




FIG. 1




FIG. 2





FIG. 3

4/14






FIG. 5

6/14




FIG. 6A

7/14




FIG. 6B

8/14




FIG. 6C






FIG. 7A



Treatment G: 200 mg milvexian (2x 100 mg film-coated DC oral tablet) BID for 5 days (administered in the morning after at least 10-hour overnight fasting and in the evening 12 hours after the morning dose)

Treatment H: 200 mg milvexian (2x 100 mg Phase 2 oral capsules: BID for 5 days (administered in the morning after at least 10-hour overnight fasting and in the evening 12 hours after the morning dose)

FIG. 7B



Treatment I: 25 mg milvexian (1x 25 mg film-coated DC oral tablet BID for 5 days (administered in the morning after at least 10-hour overnight fasting and in the evening 12 hours after the morning dose))
Treatment J: 25 mg milvexian (1x 25 mg Phase 2 oral capsule) BID for 5 days (administered in the morning after at least 10-hour overnight fasting and in the evening 12 hours after the morning dose)

FIG. 7C






FIG. 7D





†Study will be powered to adequately assess major bleeding.
‡Apixaban 2.5 mg BID for participants who meet ≥ 2 of the following characteristics (in accordance with prescribing information) Age ≥ 80 years, body weight ≤ 60 kg, or serum creatinine ≥ 1.5 mg/dL.
#After Week 52, q6monthly in-clinic visits interspersed with telephone contacts between in-clinic visits.
*GTED, Global Targeted Endpoint Date. GTED will occur when the pre-specified number of primary efficacy and safety events have occurred. In addition, the total study duration may also allow for at least 530 participants to experience an ISTH major bleeding event.

FIG. 9